Eli Lilly receives additional FDA approval for Verzenio.
Eli Lilly announced that the U.S. FDA has approved Verzenio in combination with an aromatase inhibitor as initial endocrine-based therapy for the treatment of postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced or metastatic breast cancer. This additional FDA approval marks the third indication for Verzenio within five months. In September 2017, Verzenio became the first and only cyclin-dependent kinase 4 & 6 inhibitor approved in combination and as a single agent in metastatic breast cancer. Specifically, Verzenio was approved for use in combination with fulvestrant for the treatment of women with HR+, HER2- advanced or metastatic breast cancer with disease progression following endocrine therapy, and as monotherapy for the treatment of adult patients with HR+, HER2- advanced or metastatic breast cancer with disease progression following endocrine therapy and prior chemotherapy in the metastatic setting.
|Printer friendly Cite/link Email Feedback|
|Date:||Feb 26, 2018|
|Previous Article:||Centennial Resource Development sees growing annual oil production 85% in 2018.|
|Next Article:||Citizens Financial says 'not aware' of being subject of any active investigation.|